Oricell Therapeutics raised $110 million in a pre-IPO round to expand its global footprint and advance a GPC3-targeted autologous CAR T therapy for liver cancer into registrational trial planning. The company’s lead program is designed for patients with solid tumors expressing GPC3, where response durability and manageable toxicity remain central development challenges. The financing is intended to support both operational expansion and the clinical path for the CAR T program. Oricell said it aims to move toward registrational studies, positioning the capital for the transition from early development into late-stage readouts. For the sector, the round highlights continued investor appetite for next-generation CAR T approaches beyond hematologic malignancies, as solid-tumor cell therapies seek traction in more competitive trial environments.